@article{b6d535b2b52d465ba3df9e748b432d6c,
title = "Lipid deposition and metaflammation in diabetic kidney disease",
abstract = "A critical link between metabolic disorders and a form of low-grade systemic and chronic inflammation has been recently established and named {\textquoteleft}Metaflammation{\textquoteright}. Metaflammation has been recognized as a key mediator of both microvascular and macrovascular complications of diabetes and as a significant contributor to the development of diabetic kidney disease (DKD). The goal of this review is to summarize the contribution of diabetes-induced inflammation and the related signaling pathways to diabetic complications, with a particular focus on how innate immunity and lipid metabolism influence each other.",
author = "Alla Mitrofanova and Fontanella, {Antonio M.} and Sandra Merscher and Alessia Fornoni",
note = "Funding Information: AF and SM are an investors on pending or issued patents (US 10 183 038 and US 10 052 345) aimed at diagnosing or treating proteinuric kidney diseases. They stand to gain royalties from the future commercialization of these patents. A.F. is Vice-President of L&F Health LLC and is consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&F Research for the treatment of kidney disease. A.F. is founder of LipoNexT LLC. S.M. is a consultant for Kintai Therapeutics, Inc and holds equity interest in L&F Research. AF and SM are supported by Hoffman-La Roche and by Boehringer Ingelheim . Funding Information: Research in Dr Alessia Fornoni{\textquoteright}s laboratory is supported by the National Institutes of Health [grant numbers R01DK117599 , R01DK104753 , R01CA227493 , U54DK083912 , UM1DK100846 , U01DK116101 ] and by the Miami Clinical Translational Science Institute [grant number UL1TR000460 ]. We give a special thanks to the Katz family for continuous support. Funding Information: AF and SM are an investors on pending or issued patents (US 10 183 038 and US 10 052 345) aimed at diagnosing or treating proteinuric kidney diseases. They stand to gain royalties from the future commercialization of these patents. A.F. is Vice-President of L&F Health LLC and is consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&F Research for the treatment of kidney disease. A.F. is founder of LipoNexT LLC. S.M. is a consultant for Kintai Therapeutics, Inc and holds equity interest in L&F Research. AF and SM are supported by Hoffman-La Roche and by Boehringer Ingelheim.Research in Dr Alessia Fornoni's laboratory is supported by the National Institutes of Health [grant numbers R01DK117599, R01DK104753, R01CA227493, U54DK083912, UM1DK100846, U01DK116101] and by the Miami Clinical Translational Science Institute [grant number UL1TR000460]. We give a special thanks to the Katz family for continuous support. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2020",
month = dec,
doi = "10.1016/j.coph.2020.09.004",
language = "English (US)",
volume = "55",
pages = "60--72",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
}